Sheet of POTY Sophie

POTY Sophie
Address : Université Bourgogne Europe
Institut de Chimie Moléculaire de l’Université de Bourgogne (ICMUB)
Bât. MIRANDE – Aile B – Bureau B117
9 avenue Alain Savary BP 47870
21078 DIJON Cedex - FRANCE
Phone number : +33 3 80 39 38 18
E-mail : sophie.poty@ube.fr
Team : RITM
Function : UBE Junior Professorship
Tags : Radiochemistry, Radiopharmaceutical chemistry, Preclinical evaluation, Radiobiology
ORCID : 0000-0002-5496-0758
  • CV
  • Projects
  • Publications
  • Teaching
CV

Since 2024 : Junior Professor/Chaire Professeur Junior (CPJ) UBE at ICMUB, Université de Bourgogne Europe, Dijon, France

2023-2024 : Postdoctoral fellow at ICMUB, Université de Bourgogne Europe, Dijon, France

2019-2023 : Postdoctoral fellow at Institut de Recherche en Cancérologie de Montpellier (IRCM), Montpellier, France

2016-2019 : Postdoctoral fellow at Memorial Sloan Kettering Cancer Center (MSKCC), New York, Etats-Unis

2016-2019 : PhD student at ICMUB, Université de Bourgogne Europe, Dijon, France

Projects

–           Alpha-targeted radionuclide therapy: from basic radiochemistry to multimodal approaches

–           Optimizing pretargeting approaches

–           Exploring the tumor microenvironment for nuclear medicine applications

 

Fundings:

2025-2027 : ANR-25-MRS1-0021-01 – RAD-ability

2024 : Agence national de la recherche – CPJ Targeted alpha therapy

Publications

Selected publications

  1. Versatile bifunctional PYTA derivatives for actinium-225 radiolabeling: a comparison to gold standards. Cheveau M, Moreau M, Grohmann A, Robert S, Cochet A, Collin B, Boschetti F, Poty S, Denat F. Just accepted in J Nucl Med.
  2. Optimizing the therapeutic index of sdAb-based radiopharmaceuticals using a pretargeting strategy. Poty S, Ordas L, Dekempeneer Y, Parach AA, Navarro L, Santens F, Bardiès M, Lahoutte T, D’Huyvetter M, Pouget JP. J Nucl Med. 2024 Oct 1;65(10):1564-1570.
  3. 89Zr-PET imaging of DNA double-strand breaks for the early monitoring of response following α- and β-particle radioimmunotherapy in a mouse model of pancreatic ductal adenocarcinoma. Poty S, Mandleywala K, O’Neill E, Knight JC, Cornelissen B, Lewis JS. Theranostics., 10(13), 5802-5814, (2020).
  4. Leveraging Bioorthogonal Click Chemistry to Improve 225Ac-Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma. Poty S, Carter LM, Mandleywala K, Membreno R, Abdel-Atti D, Ragupathi A, Scholz WW, Zeglis BM, Lewis JS. Clin Cancer Res., 25(2), 868-880, (2019).
  5. α-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies-Part 2. Poty S, Francesconi LC, McDevitt MR, Morris MJ, Lewis JS. J Nucl Med., 59(7), 1020-1027, (2018).
  6. α-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies-Part 1. Poty S, Francesconi LC, McDevitt MR, Morris MJ, Lewis JS. J Nucl Med., 59(6), 878-884, (2018).
  7. The inverse electron-demand Diels-Alder reaction as a new methodology for the synthesis of 225Ac-labelled radioimmunoconjugates. Poty S, Membreno R, Glaser JM, Ragupathi A, Scholz WW, Zeglis BM, Lewis JS. Chem Commun (Camb)., 54(21), 2599-2602, (2018).
  8. AMD3100: A Versatile Platform for CXCR4 Targeting 68Ga-Based Radiopharmaceuticals. Poty S, Gourni E, Désogère P, Boschetti F, Goze C, Maecke HR, Denat F. Bioconjug Chem., 27(3), 752-761, (2016).
  9. MANOTA: a promising bifunctional chelating agent for copper-64 immunoPET. Moreau M, Poty S, Vrigneaud JM, Walker P, Guillemin M, Raguin O, Oudot A, Bernhard C, Goze C, Boschetti F, Collin B, Brunotte F, Denat F. Dalton Trans., 46(42), 14659-14668, (2017).

 

Full list (HAL)

Sophie Poty, Laura Ordas, Yana Dekempeneer, Ali Asghar Parach, Laurent Navarro, et al.. Optimizing the Therapeutic Index of sdAb-Based Radiopharmaceuticals Using Pretargeting. Journal of Nuclear Medicine, 2024, 65 (10), pp.1564-1570. ⟨10.2967/jnumed.124.267624⟩. ⟨hal-05039476⟩
Sophie Poty, Pauline Désogère, Christine Goze, Frédéric Boschetti, Thomas d'Huys, et al.. New AMD3100 derivatives for CXCR4 chemokine receptor targeted molecular imaging studies: synthesis, anti-HIV-1 evaluation and binding affinities. Dalton Transactions, 2015, 44 (11), ⟨10.1039/c4dt02972k⟩. ⟨hal-05039470⟩
Yara Al Ojaimi, Timothée Blin, Juliette Lamamy, Matthieu Gracia, Aubin Pitiot, et al.. Therapeutic antibodies – natural and pathological barriers and strategies to overcome them. Pharmacology and Therapeutics, 2021, pp.108022. ⟨10.1016/j.pharmthera.2021.108022⟩. ⟨hal-03531953⟩
Tristan Mangeat, Matthieu Gracia, Alexandre Pichard, Sophie Poty, Pierre Martineau, et al.. Fc-engineered monoclonal antibodies to reduce off-target liver uptake. EJNMMI Research, 2023, 13 (1), pp.81. ⟨10.1186/s13550-023-01030-0⟩. ⟨hal-04598633⟩
Clara Diaz Garcia-Prada, Léna Carmès, Salima Atis, Ali Parach, Alejandro Bertolet, et al.. Gadolinium-Based Nanoparticles Sensitize Ovarian Peritoneal Carcinomatosis to Targeted Radionuclide Therapy. Journal of Nuclear Medicine, 2023, 64 (12), pp.1956-1964. ⟨10.2967/jnumed.123.265418⟩. ⟨hal-04393804⟩
Guillaume Thomas, Julien Boudon, Lionel Maurizi, Mathieu Moreau, Paul Walker, et al.. Innovative Magnetic Nanoparticles for PET/MRI Bimodal Imaging. ACS Omega, 2019, 4 (2), pp.2637-2648. ⟨10.1021/acsomega.8b03283⟩. ⟨hal-02068644⟩
M. Moreau, Sophie Poty, J-M Vrigneaud, P. Walker, M. Guillemin, et al.. MANOTA: a promising bifunctional chelating agent for copper-64 immunoPET. Dalton Transactions, 2017, 46 (42), pp.14659-14668. ⟨10.1039/c7dt01772c⟩. ⟨hal-01620489⟩
Mathieu Moreau, Sophie Poty, J.M. Vrigneaud, Paul Walker, M. Guillemin, et al.. MA-NOTA: a new chelator for efficient Cu-64 antibody radiolabeling. Annual Congress of the European Association of Nuclear Medicine, Oct 2016, Barcelone, Spain. pp.S176-S177 / OP588, ⟨10.1007/s00259-016-3484-4⟩. ⟨hal-01478019⟩
Sophie Poty, Eleni Gourni, Pauline Désogère, Frédéric Boschetti, Christine Goze, et al.. AMD3100: A Versatile Platform for CXCR4 Targeting 68 Ga-Based Radiopharmaceuticals. Bioconjugate Chemistry, 2016, 27 (3), pp.752 - 761. ⟨10.1021/acs.bioconjchem.5b00689⟩. ⟨hal-01390153⟩
Teaching

Since 2024
Chaire Professeur Junior (Junior Professorship)

64 teaching hours/year

– 35h/year Radiochemistry (Lecture courses + Tutorial work) – Master degree level

– 18h/year Molecular Imaging (Lecture courses + Tutorial work) – Master degree level

– 9h/year Radiometals (Lecture courses + Tutorial work) – Master degree level

– 2h/year Radiotheranostics (Lecture courses) – Master degree level

Since 2024
Co-supervision of PhD students (Maxime Cheveau 2022-2025, Tatjana Cwojdzinski 2024-2027)

2020-2023
Institut de Recherche en Cancérologie de Montpellier co-supervision of PhD student (Laura Ordas, 2020-2023)